Latar belakang: Kadar serum CA 125 telah diketahui mengalami peningkatan pada kasus limfoma non Hodgkin. Kegunaannya dalam menentukan prognosis, tingkat keparahan penyakit, dan follow up pasca terapi limfoma non Hodgkin telah banyak diteliti dan masih didapatkan hasil yang bervariasi. Saat ini belum diketahui mengenai kadar serum CA 125 pada kasus diffuse large B cell lymphoma (DLBCL) yang bermanifestasi di regio kepala dan leher. Tujuan: Mengetahui hubungan kadar serum CA 125 dengan karakteristik klinis pada kasus DLBCL regio kepala dan leher. Metode: Penelitian ini merupakan penelitian potong lintang yang melibatkan 31 subjek penelitian dengan diagnosis DLBCL regio kepala dan leher. Dilakukan pencatatan karakteristik klinis dan penentuan kadar serum CA 125 dengan pemeriksaan Immunoasai dan kemudian dilakukan analisis statistik untuk menentukan hubungan antar variabel. Hasil: Didapatkan peningkatan kadar serum CA 125 pada stadium lanjut dengan p<0,001. Analisis statistik terhadap kadar serum CA 125 dan Kadar Lactic Dehydrogenase (LDH) menunjukkan hubungan yang signifikan (p=0,018) demikian juga hubungannya dengan skorEastern Cooperative Oncology Group (ECOG) dengan nilai p=0,001. Pada penelitian ini tidak terdapat hubungan yang bermakna antara kadar serum CA 125 dengan skor Prognostic International Index (IPI). Kesimpulan: Kadar serum CA 125 berhubungan bermakna dengan stadium klinis, kadar LDH dan Skor ECOG pada DLBCL yang bermanifestasi di regio kepala dan leher. Dengan demikian CA 125 dapat digunakan sebagai marker untuk memprediksi prognosis dan mendekati stadium lanjut kasus limfoma non Hodgkin. Background: Serum CA 125 level has been known to increase in Non-Hodgkin Lymphoma cases.Many studies had elaborately researched the prognosis, disease severity and the follow up of Non Hodgkin Lymphoma cases using CA 125, yet the results had been varied. Up to now, serum CA 125 levels in cases of diffuse large B cell lymphoma (DLBCL) which manifest in the head and neck region, is still unclear. Purpose: To find out the correlation of serum CA 125 levels with clinical manifestations of DLBCL cases in the head and neck region. Method: A cross-sectional study involving 31 subjects diagnosed with DLBCL in the head and neck region. The clinical manifestations were recorded and serum CA 125 levels were obtained by Immunoassay examination. Statistical analysis was performed to determine the correlation between variables. Results: An increase in serum CA 125 levels at an advanced stage with p <0.001. The statistical result of CA 125 serum levels and LDH levels showed a significant correlation (p=0.018), as well as its significant correlation with the Eastern Cooperative Oncology Group (ECOG) score, with p=0.001. In this study there was no significant correlation between CA 125 serum levels and Prognostic International Index (IPI) scores. Conclusion: Serum CA 125 levels were significantly correlated with clinical stage, LDH level and ECOG score of DLBCL which manifested in the head and neck region. Therefore, CA 125 might be used as a marker to predict prognosis and to detect advanced disease in Non-Hodgkin Lymphoma cases.

Background: Diffuse Large B-Cell Lymphoma (DLBCL) is the most common subtype of the Non-Hodgkin Lymphoma (LNH). Until now, lactate dehydrogenase (LDH) is the only tumor marker to assess DLBCL progression; however, increased LDH is a relatively non-specific biomarker. Cancer antigen 125 (CA-125) serum level have been used as a tumor marker in ovarian cancer. The aim of this study was to explore the possible role of CA-125 serum level as a tumor marker in head and neck DLBCL. Methods: This was an observational descriptive study among consecutively sampled DLBCL patients. CA-125 serum level examination was carried out (ADVIA Centaur CA-125II) and described along with the clinical characteristics of DLBCL patients. Results: DLBCL was mostly observed in males (54.05%), most often in the 55-65 year age group (51.3%), with stage 1 DLBCL was the most prevalent (71.9%). The mean CA-125 serum level was 22.9 U/ml and increased in patients with advanced DLBCL. Conclusions: Increased CA-125 serum level in DLBCL, especially at advanced stages, suggests that CA-125 serum level may be of benefit as a tumor marker in the head and neck DLBCL. Further study is in need to explore the role of CA-125.